Global Multi Cancer Early Detection market

Report ID : 1408 | Published : 2022-10-14 | Pages: | Format: PDF/EXCEL

The market size of the global multi cancer early detection market in the year 2021 is valued at 803.54 million and is predicted to reach 2636.89 million by the year 2030 at an 14.49% CAGR during the forecast period.

Multi-cancer early detection is a novel technique for spotting cancer in its early stages. Multi Cancer Early Detection is a novel technique for spotting cancer in its early stages. The test searches for certain antigens released into cancer patients' blood. There are numerous distinct cancer kinds, and each type has its collection of indicators. The Multi Cancer Early Detection test scans the blood of cancer patients for a particular set of markers. The market for multi-cancer early detection (MCED) is anticipated to grow due to factors including the rising incidence of cancer and the increased government emphasis on the early detection of cancers. The market presents a significant opportunity, given a growing understanding that early cancer detection can improve patient survival and lower treatment costs. The development of MCED is undergoing extensive Research &Development to improve diagnostic performance. Additionally, the creation of tests that can precisely and continuously look for indications of a wide range of malignancies, the majority of which lack an effective screening method, is anticipated to fuel the expansion of the entire market.

Along with these other aspects, firms functioning in the global green chemicals market can anticipate profitable revenue growth potential due to rising R&D activities, government initiatives to employ sustainable components in production and investments from well-known companies.

Market Segmentation:

The multi cancer early detection market is segmented based on product and end user. Based on type, the market is segmented as liquid biopsy and gene panel, LDT and Others. By end user, the market is segmented into hospitals, diagnostic laboratories and other.

Based on type, the liquid biopsy segment is accounted as a major contributor in the multi cancer early detection market

The liquid biopsy category is expected to hold a major share in the global multi-cancer early detection market in 2021. Cancer detection's great uptake and acceptance are credited with the segment's supremacy. One of the innovative and newest advances in diagnostics is a liquid biopsy which is expected to drive the market further.

Hospital’s sector witnessed growth at a rapid rate in the market

The hospital segment is projected to grow at a rapid rate in the global multi-cancer early detection market. Medical professionals with specialized training and other healthcare workers involved in diagnosis and treatment are responsible for this segment's dominance. Hospitals inform and raise public knowledge of various illnesses and ailments. The target audience knows very little about MCED, a new technology. As a result, hospitals examine asymptomatic people for several types to facilitate therapy, especially in countries such as the US, Germany, the UK, China, and India.

The North America multi cancer early detection market holds the biggest revenue share.

The North American multi-cancer early detection market. Some major components propelling market expansion in North America are the increasing cancer frequency, the accessibility of cutting-edge medical infrastructure, and the involvement of significant players here. In addition, Asia Pacific is accounted to hold the highest share in the global multi-cancer early detection market. One of the key reasons propelling market expansion in this region is the escalating disease population and the expanding government measures to improve early cancer detection.

Competitive Landscape

Some of the major key players in the multi cancer early detection market are Grail, LLC (Illumina, Inc.), Exact Sciences Corporation, Foundation Medicine, Inc., AnchorDx, Guardant Health, Inc., Burning Rock Biotech Limited, GENECAST, Laboratory for Advanced Medicine, Inc., and Singlera Genomics Inc.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Multi Cancer Early Detection Market Snapshot

Chapter 4. Global Multi Cancer Early Detection Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis

5.1. by Product Type & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn) & Volume (no. of units) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Product Type:

5.2.1. Liquid Biopsy

5.2.2. Gene Panel, LDT and Others

Chapter 6. Market Segmentation 2: by End-users Estimates & Trend Analysis

6.1. by End-users & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn) & Volume (no. of units) & Forecasts and Trend Analyses, 2019 to 2030 for the following by End-users:

6.2.1. Hospitals

6.2.2. Diagnostic Laboratories

6.2.3. Others

Chapter 7. Multi Cancer Early Detection Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Multi Cancer Early Detection Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2030

7.1.2. North America Multi Cancer Early Detection Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2030

7.1.3. North America Multi Cancer Early Detection Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2030

7.2. Europe

7.2.1. Europe Multi Cancer Early Detection Market revenue (US$ Million) by Product Type, 2019-2030

7.2.2. Europe Multi Cancer Early Detection Market revenue (US$ Million) by End-users, 2019-2030

7.2.3. Europe Multi Cancer Early Detection Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Multi Cancer Early Detection Market revenue (US$ Million) by Product Type, 2019-2030

7.3.2. Asia Pacific Multi Cancer Early Detection Market revenue (US$ Million) by End-users, 2019-2030

7.3.3. Asia Pacific Multi Cancer Early Detection Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America Multi Cancer Early Detection Market revenue (US$ Million) by Product Type, 2019-2030

7.4.2. Latin America Multi Cancer Early Detection Market revenue (US$ Million) by End-users, 2019-2030

7.4.3. Latin America Multi Cancer Early Detection Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Multi Cancer Early Detection Market revenue (US$ Million) by Product Type, 2019-2030

7.5.2. Middle East & Africa Multi Cancer Early Detection Market revenue (US$ Million) by End-users, 2019-2030

7.5.3. Middle East & Africa Multi Cancer Early Detection Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Gralic, LLC (Illumina, Inc)

8.2.2. Exact Sciences Corporation

8.2.3. Foundation Medicine, Inc

8.2.4. AnchorDx

8.2.5. Guardant Health

8.2.6. Buring Rock Biotech Limited

8.2.7. GENECAST

8.2.8. Labporatory for Advanced Medicine, Inc.

8.2.9. Singlera Genomics Inc

8.2.10. Other Prominent Players

By Type

  • Liquid Biopsy
  • Gene Panel, LDT and Others

By End Use

  • Hospitals
  • Diagnostic Laboratories
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients